Across TCGA pan-cancer cohorts, KRTAP5-2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP5-2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher KRTAP5-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP5-2 expression acts as an unfavorable survival marker.

STAD, DLBC, and COAD are the cancer types where KRTAP5-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
COAD	OS	Median	II,III,IV	0.556	0.850	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP5-2 tumor-vs-normal RNA expression · all KRTAP5-2 data types